首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1562318

北美人疫苗佐剂市场预测至 2030 年 - 区域分析 - 按类型、应用（流感、肝炎、人类乳突病毒等）和最终用户

North America Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 109 Pages | 订单完成后即时交付

价格

简介目录图表

2022年北美人疫苗佐剂市场估值为65,608万美元，预计2030年将达到18,3801万美元；预计2022年至2030年复合年增长率为13.7%。

慢性病盛行率上升推动北美人用疫苗佐剂市场

慢性病盛行率的上升推动了对疫苗佐剂的需求。疫苗中添加佐剂以增强功效和身体的免疫反应。它们透过刺激更强、更持久的免疫反应来帮助提高疫苗的有效性。随着预防和管理慢性病的疫苗需求持续成长，佐剂的需求也随之增加。心血管疾病、癌症、糖尿病和呼吸系统疾病等慢性病在全球呈现上升趋势。据世界卫生组织称，与非传染性疾病相关的死亡人数最多的是心血管疾病，每年造成 1700 万人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括与肾臟相关的死亡）。此外，根据世界心臟联盟的数据，高胆固醇每年导致 440 万人死亡，约 24% 的心血管相关死亡可归因于高低密度脂蛋白 (LDL) 胆固醇。因此，慢性病负担的增加导致对能够预防或控制这些疾病的疫苗的需求不断增长。老年人口的增加也增加了对疫苗的需求。 NCBI 2023 年 1 月发布的一项研究显示，到 2050 年，美国 50 岁及以上人口将达到 22113 万人，较 2020 年的 13725 万人快速增长。，预计这一数字将从2020 年的7152 万人增加到2050 年的1.4266 万人，增长99.5%。是也在增加。肝炎疫苗中的佐剂旨在引发强大而持久的免疫力，特别是对标准疫苗配方反应不佳的人群，例如患有潜在疾病或与年龄相关的免疫衰老的人群。据世界卫生组织称，全世界有超过 3.5 亿人患有乙型或丙型肝炎。根据世界卫生组织的一项研究，到 2030 年，低收入和中等收入国家估计可透过疫苗接种预防 450 万人因肝炎而过早死亡。因此，慢性病盛行率的增加推动了北美人类疫苗佐剂市场的成长。

北美人用疫苗佐剂市场概况

美国在北美人类疫苗佐剂市场中占有重要份额。该国的市场成长主要归因于政府医疗保健支出的增加以及对新型疫苗配方的需求激增，以更有效地治疗传染病。根据美国医疗保险和医疗补助服务中心的数据，2021 年美国国民医疗保健支出成长 2.7%，达到 4.3 兆美元，即人均 12,914 美元。医疗卫生支出占全国GDP的18.3%。美国卫生与公众服务部预计，2019-2028年国家卫生支出将以年均5.4%的速度增长，到2028年将达到6.2万亿美元。刺激了对人用疫苗佐剂的需求。根据 2020 年 7 月发布的全球疾病负担研究的新发现，美国的非传染性疾病和传染病负担巨大且不断增加。据约翰霍普金斯大学称，近二十年来，美国SARS、莱姆病、登革热、西尼罗河病毒、寨卡病毒等疾病感染病例迅速增加。此外，同一消息来源也证实，疟疾、结核病、霍乱、百日咳、流感、肺炎球菌疾病和淋病等重新出现的疾病的发生率增加。同样，根据美国疾病管制与预防中心 (CDC) 的数据，2010 年至 2022 年间，流感每年导致 100,000 至 710,000 人住院治疗，4,900 至 52,000 人死亡。有1.405 亿15 岁及以上女性面临HPV 相关子宫颈癌的风险。在美国普通人群中，预计有近 3.9% 的女性在特定时间携带子宫颈 HPV16/18 感染，71.2% 的浸润性子宫颈癌归因于 HPV 16 或 18。方面的努力，推动了美国北美人类疫苗佐剂市场的成长。美国政府努力为在该国开发和商业化药品和保健产品创造有利的环境。该国拥有多个潜在的製药和医疗器材市场参与者，包括辉瑞、诺华、波士顿科学、Integra LifeSciences、安进和雅培，其製药和医疗器材行业创新拥有各种专利。因此，各製药巨头药物开发活动的增加提振了美国的北美人疫苗佐剂市场。

北美人类疫苗佐剂市场收入及 2030 年预测（百万美元）

北美人用疫苗佐剂市场区隔

北美人疫苗佐剂市场按类型、应用、最终用户和国家分类。

依类型，北美人疫苗佐剂市场分为颗粒佐剂、乳液佐剂、组合佐剂等。 2022 年，颗粒助剂领域占最大的市场份额。

从应用来看，北美人疫苗佐剂市场分为流感、肝炎、人类乳突病毒（HPV）等。 2022 年，流感细分市场占据最大市场。

依最终用户划分，北美人疫苗佐剂市场分为製药和生技公司、CMO 和 CRO 等。 2022 年，製药和生物技术公司细分市场占据最大市场份额。

依国家划分，北美人疫苗佐剂市场分为美国、加拿大和墨西哥。 2022年，美国在北美人类疫苗佐剂市场份额中占据主导地位。

Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是北美人类疫苗佐剂领域的领先公司市场。

The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ?17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The rising geriatric population is also bolstering the demand for vaccines. As per a study published in January 2023 by NCBI, in the US, the number of people aged 50 years and older will reach 221.13 million by 2050, a rapid increase from 137.25 million in 2020. People aged 50 and above are expected to suffer from at least one chronic disease, and the figure is projected to rise by 99.5% from 71.52 million in 2020 to 142.66 million by 2050. Also, it is projected that ~14 million people are likely to suffer from multimorbidity by 2050 The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the North America human vaccine adjuvants market.

North America Human Vaccine Adjuvants Market Overview

The US holds a significant share of the North America human vaccine adjuvants market in North America. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the North America human vaccine adjuvants market growth in the US. The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the North America human vaccine adjuvants market in the US.

North America Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Human Vaccine Adjuvants Market Segmentation

The North America human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the North America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the North America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the North America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the North America human vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are among the leading companies operating in the North America human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 North America Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - North America Market Analysis

5.1 North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 North America Human Vaccine Adjuvants Market Forecast Analysis

6. North America Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Human Vaccine Adjuvants Market - Country Analysis

9.1 North America
- 9.1.1 North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 US Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 US Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 US Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Canada Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 Canada Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 Canada Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Mexico Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 Mexico Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 Mexico Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hawaii Biotech Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Croda International Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Novavax Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Phibro Animal Health Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Creative Biolabs Inc
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

简介目录图表

List Of Tables

Table 1. North America Human Vaccine Adjuvants Market Segmentation
Table 2. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 16. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. North America Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. North America Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)